Accelerate to discover

Back to filter

Related topics

Introducing Cytek Cloud

Cytek Biosciences

Dec 1, 2022

Cytek Cloud is the new digital ecosystem that supports full spectrum flow cytometry research from panel design to data...

See More, Sort More with Cytek Full Spectrum Systems

Cytek Biosciences

Nov 28, 2022

Still wondering whether to join the shift to full spectrum cytometry?  Easily transfer assays from your Cytek Northern...

Demonstrate the value of RareCyte Orion system via web-based Minerva viewer

RareCyte

Nov 25, 2022

The HTA CRC Atlas X dataset contains images and other data being used for construction of an atlas of human colorectal...

ACCELA Educational webinar series: Unlocking Spatial Biology with RareCyte Orion Technology

RareCyte

Nov 16, 2022

Discover full slide, high-plex biomarker quantitation with the all-in-one spatial biology...

Dec 8, 2022

Practical aspects of an imaging study: live in vivo scanning

MOLECUBES

Nov 11, 2022

In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...

All inside your incubator: xCELLigence eSight

Agilent technologies

Nov 3, 2022

Multiplex Live cell imaging and real-time biosensor measurement with xCELLigence eSight

Download the newest AVATAR data presented at CAR-TCR

Xcell Biosciences

Oct 21, 2022

Xcell Bio CSO, James Lim, presented new data showcasing improved potency of AVATAR-expanded CAR T cells and highlighted...

Dec 8, 2022

RareCyte Orion system advances Multi-modal digital pathology for colorectal cancer diagnosis

RareCyte

Oct 19, 2022

Precision medicine is critically dependent on better methods for diagnosing and staging disease and predicting drug...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Related technologies: Real-time, label free cell analysis

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey